Slide 1: Investor Presentation: Business Update
1 INVESTOR P RE S E N T A T I O N BUSINESS UPDATE 19 APRIL, 2023 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections . Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended t
Slide 3: Executive Summary
3 EXE C UT IV E S U MMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases C o m pa n y O v e r vie w • Two commercially available oral immunotherapeut
Slide 4: Key Commentary: Sales Year to Date 14 April 2023
4 Key Commentary • Strong start to Q4 2023 (to 14 April 2023) • $320k Net Sales; up 233% YTD on pcp • Supply chain capacity addressed by contracting another packaging supplier • Australian wholesalers and retail pharmacies now fully stocked • Building stock to allow accelerated growth in internation
Slide 5: Key Milestones Anticipated to Drive Value
5 K E Y MILES T O NE S AN T I C I P A T E D T O D RIV E V AL UE 2H 2022 1H 2023 2H 2023 1H 2024 Travelan® • FDA IND 1 approved for single daily dose IMM - 124E ETEC 2 CHIM 3 clinical trial a • IRB Approval 4 • Initiate IMM - 124E ETEC CHIM clinical trial • Topline results for IMM - 124E ETEC CHIM cl
Slide 6: Steven Lydeamore, Chief Executive Officer: Contact Information
Steven Lydeamore Chief Executive Officer Immuron Limited 19 April 2023 Contact Information: Phone: Australia: +613 8892 4854 Email: steve@immuron.com
Slide 7: Technology Platform
7 STEP 1 STEP 2 STEP 3 FINAL PRODUCT Development of Highly Specific Vaccines Isolation of Hyperimmune antibody - rich bovine colostrum Oral Antimicrobial therapeutics without drawbacks of antibiotics Toxin Neutralization + Clearance of targeted gut pathogens TECHNOLOGY PLATFORM Immuron’s proprietary
Slide 8: Addressable Market & Industry Overview
8 ADDRESSABLE MARKET & INDUSTRY OVERVIEW Billion Dollar Market Travelers diarrhea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveler’s diarrhea*** * I Q V I A
Slide 9: Lumanity Opportunity Assessment for IMM-124E
9 Lumanity* Opportunity Assessment for IMM - 124E b • Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need • Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% pr
Slide 10: Scientific References
10 SCIENTIFIC REFERENCES T r a v e l a n® (I MM - 124 E ) Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan as a broad Spec
Slide 11: ASX Releases Referenced
11 ASX RELEASES REFERENCED Ref Slide statement ASX Release a Travelan® (IMM - 124E) IND filed with and approved by FDA Immuron Receives FDA Approval for Travelan IND Application b Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) AGM Present